Table 3.
Factors Predicting Higher Relative Dose Intensity
| Variable | Estimate | 95% CI | p-value |
|---|---|---|---|
| Cycle 1 | |||
| Male Gender | 0.083 | 0.03–0.15 | 0.0047 |
|
| |||
| Distance (≥90 miles) from UWCCC | 0.088 | 0.03–0.14 | 0.0034 |
|
| |||
| Performance Status (0 vs. 1 or 2) | 0.088 | 0.03–0.14 | 0.0025 |
|
| |||
| Disease Stage (metastatic versus local) | 0.204 | 0.09–0.32 | 0.0004 |
|
| |||
| All Cycles* | |||
| Male Gender | 0.050 | 0.02–0.08 | 0.0027 |
|
| |||
| Distance (≥90 miles) from UWCCC | 0.052 | 0.02–0.09 | 0.0041 |
|
| |||
| Performance Status (0 vs 1 or 2) | 0.097 | 0.06–0.13 | 0.54 |
|
| |||
| Disease Stage (metastatic vs. local) | 0.076 | 0.00–0.16 | <0.0001 |
|
| |||
| Trial Phase (I vs. II–III) | 0.138 | 0.07–0.21 | <0.0001 |
|
| |||
| Performance Status*Stage | 0.238 | 0.10–0.37 | 0.0006 |
*
Controlled for time on study and cycle number